◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › N › NTLA

Intellia Therapeutics Inc (NTLA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-13

Intellia Therapeutics Inc (NTLA) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 377 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, NTLA reported $68M in revenue and ($413M) in net income.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Interactive charts & full statements → Open the NTLA valuation workbench →

NTLA Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Total Revenue$60M$68M$58M$36M$52M$33M$58M$43M$30M$26M$16M$6M$0M
Gross Profit($27M)$52M$48M$27M$45M$33M$58M($65M)$30M$26M$16M($5M)($2M)
Gross Margin %-45.0%76.5%82.2%75.3%85.5%100.0%100.0%-151.5%100.0%100.0%100.0%-84.8%—
Operating Income (EBIT)($424M)($441M)($534M)($515M)($458M)($268M)($137M)($106M)($91M)($70M)($32M)($13M)($5M)
Operating Margin %-706.7%-651.7%-923.1%-1420.5%-879.0%-810.4%-235.5%-246.8%-298.6%-266.3%-195.2%-221.9%—
Net Income($400M)($413M)($519M)($481M)($474M)($260M)($126M)($100M)($85M)($68M)($32M)($12M)($14M)
Net Margin %-666.7%-609.8%-896.8%-1326.5%-909.8%-785.8%-216.5%-230.9%-280.4%-258.6%-192.0%-205.1%—
EBITDA($390M)($397M)($509M)($472M)($467M)($261M)($130M)($101M)($86M)($67M)($31M)($13M)($10M)
Earnings Per Share (EPS)$-3.41$-3.81$-5.25$-5.42$-6.16$-3.66$-2.24$-2.11$-1.98$-1.88$-0.91$-0.70$-1.39
Shares Outstanding (M)133M108M99M89M77M71M56M47M43M36M35M18M10M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NTLA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$8M$15M$23M$14M$14M$17M$13M$9M
Gross Profit$8M$13M$17M($65M)($66M)$17M($104M)($100M)
Gross Margin %100.0%85.4%73.9%-472.8%-465.3%100.0%-807.9%-1098.3%
Operating Income (EBIT)($113M)($101M)($99M)($111M)($110M)($121M)($136M)($145M)
Operating Margin %-1472.2%-668.1%-428.9%-808.9%-772.2%-726.6%-1059.9%-1589.0%
Net Income($107M)($96M)($96M)($101M)($101M)($114M)($129M)($136M)
Net Margin %-1392.3%-639.5%-416.2%-735.2%-710.8%-687.6%-1001.2%-1489.5%
EBITDA($105M)($94M)($95M)($96M)($99M)($112M)($126M)($133M)
Earnings Per Share (EPS)$-0.80$-0.81$-0.88$-0.92$-0.98$-1.10$-1.27$-1.34
Shares Outstanding (M)133M118M108M110M104M104M102M101M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NTLA Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Cash from Operations (CFO)($346M)($349M)($349M)($394M)($333M)($225M)($50M)($103M)($61M)($65M)$36M($2M)($3M)
Capital Expenditures (CapEx)$2M$6M$6M$14M$58M$13M$4M$7M$6M$10M$6M$3M$0M
Free Cash Flow (FCF)($348M)($355M)($355M)($408M)($392M)($238M)($53M)($110M)($68M)($75M)$30M($4M)($4M)
FCF Margin %-580.0%-524.1%-612.8%-1124.9%-751.5%-719.4%-92.2%-255.3%-222.2%-288.6%181.7%-71.4%—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NTLA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($83M)($117M)($69M)($77M)($100M)($149M)($85M)($85M)
Capital Expenditures (CapEx)$2M$0M$0M$0M$0M$1M$1M$1M
Free Cash Flow (FCF)($85M)($117M)($69M)($77M)($100M)($150M)($86M)($86M)
FCF Margin %-1062.5%-780.3%-301.6%-558.2%-701.0%-900.1%-669.4%-945.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NTLA Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Total Assets$857M$842M$1.2B$1.3B$1.5B$1.3B$676M$334M$347M$376M$299M$82M$11M
Cash & Cash Equivalents$106M$155M$189M$227M$524M$123M$160M$57M$59M$341M$273M$76M$10M
Total Liabilities$129M$171M$319M$251M$285M$254M$149M$64M$69M$76M$89M$15M$3M
Total Debt (Short + Long-Term)$23M$26M$20M$19M$17M$9M$6M$6M$0M$0M$0M$0M$0M
Total Shareholders' Equity$728M$671M$872M$1.1B$1.2B$1.0B$527M$270M$278M$301M$210M$67M$8M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NTLA viewer.

Other Companies in BIOTECHNOLOGY

← NTICAll “N” companiesNTML →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.